Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

Conditions: Systemic Lupus Erythematosus Interventions: Drug: Placebo; Drug: Ianalumab Sponsors: Novartis Pharmaceuticals Not yet recruiting

Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials